Evidence map›Paper›PMID 35656408›Full record

ArticleFrontiers in cellular neuroscience2022

Commentary: Current Status of Gene Therapy for Spinal Muscular Atrophy.

Wilfried Rossoll, Ravindra N Singh

Abstract readComment
In one paragraph

Article in Frontiers in cellular neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Clinical perspectives: Treating spinal muscular atrophy.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Wilfried RossollDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, United States.
Ravindra N SinghDepartment of Biomedical Sciences, Iowa State University, Ames, IA, United States.

Funding

High-throughput Screen for Discovery of Ciliary Neurotrophic Factor (CNTF) Receptor Agonists for the Treatment of Amyotrophic Lateral Sclerosis (ALS)R33NS110960 · NINDS · MAYO CLINIC JACKSONVILLE · PI ROSSOLL, WILFRIED · 2020 to 2021
$893k
NINDS NIH HHS R33 NS110960
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AAV9AVXS-101gene therapyonasemnogene abeparvovecspinal muscular atrophy (SMA)Survival Motor Neuron (SMN)Zolgensma

Identifiers

PMID35656408
PMCPMC9152110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.